ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

ImageneBio IncNASDAQ: IMA

Total Assets · Q1 FY2026 · quarter ended Mar 2026

Total assets rises 4.5% from a year ago

Total assets stood at $136.68M at the end of Q1 FY2026, up 4.5% from a year earlier and down 10.7% from the prior quarter. Over 3 fiscal years it compounded at -3.9% a year.

Context

  • Total assets increased in 2 of the last 3 fiscal years.

What to watch

Whether total assets keeps rising in the next quarterly balance sheet after a +4.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$136.68M-10.7% QoQ
Last fiscal yearDec 2025
$152.98M+8.1% YoY
Year agoMar 2025
$130.84M+4.5% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.5%——
1 year+8.1%——
3-year CAGR-3.9%——
5-year CAGR——
10-year CAGR——

Total Assets history

USD · from the balance sheet

Latest · FY2025
152.98M USD
Year-over-year change
+8.1%
4-year CAGR
-11.4%

Total Assets vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +4.5% is the 4th highest of 9, against a peer median of -30.7%.
  • Over three fiscal years its annual growth of -3.9% compares with a peer median of -9.8%.
IMA Competitors
Total Assets for IMA and competitors
Company Period Latest balance YoY 3-year CAGR
STROSutro Biopharma, Inc.Mar 2026$241.99M USD-24.7%-24.7%
OVIDOvid Therapeutics Inc.Mar 2026$225.63M USD+176.3%-0.9%
IMAImageneBio IncMar 2026$136.68M USD+4.5%-3.9%
KLRSKalaris Therapeutics IncMar 2026$109.81M USD+6.5%+214.9%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$105.96M USD-44.6%-0.5%
STTKShattuck Labs, Inc.Mar 2026$102.12M USD+32.3%-23.7%
CNTXContext Therapeutics Inc.Mar 2026$58.86M USD-36.7%+21.7%
CNTBConnect Biopharma Holdings LimitedDec 2025$56.08M USD-44.6%-31.4%
IFRXInflaRx N.V.Mar 2026€48.94M EUR-43.7%-18.6%
Peer median (excluding IMA) —-30.7%-9.8%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents232.22M59.92M119.89M39.39M34.97M
Short-term Investments097.03M55.57M84.99M40.82M
Net Receivables00001.3M
Inventory00000
Other Current Assets629K964K1.15M2.78M63.21M
Total Current Assets236.52M160.01M178.66M127.17M140.29M
Property, Plant & Equipment (Net)8.98M8.46M8.02M4.23M790K
Goodwill00000
Intangible Assets00000
Long-term Investments2.39M0000
Tax Assets00000
Other Non-current Assets03.79M5.41M10.11M11.9M
Total Non-current Assets11.36M12.25M13.43M14.34M12.69M
Total Assets247.88M172.26M192.09M141.51M152.98M
Account Payables2.38M2.09M2.07M897K1.44M
Short-term Debt00000
Tax Payables00000
Deferred Revenue17.1M9.16M000
Other Current Liabilities2.84M5.11M3.4M1.75M7.53M
Total Current Liabilities27.19M21.5M14.21M10.78M11.23M
Long-term Debt00007.02M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)7.68M0000
Other Non-current Liabilities00950K1.06M870K
Total Non-current Liabilities12.81M3.79M8.13M4.8M8.6M
Total Liabilities40M25.29M22.34M15.58M19.84M
Common Stock36K36K48K48K11K
Retained Earnings(145.45M)(214.22M)(282.39M)(331.62M)(230.05M)
Accumulated OCI0(763K)(48K)68K87K
Other Stockholders Equity00000
Minority Interest00000
Total Equity207.88M146.97M169.76M125.93M133.14M
Total Debt6.99M5.69M10.74M7.52M10M
Net Debt(225.23M)(54.23M)(109.16M)(31.87M)(24.97M)

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.